Hamden-based Vanessa Research is changing its name to Vanessa Biotech.
The company name remains a tribute to Professor Vanessa Ameen, whose research laid the foundation for the company’s flagship product Shylicine™, the first-ever drug developed to treat the rare and often lethal genetic pediatric disorder known as microvillus inclusion disease.